Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Trump

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomasK Antman, J Crowley, S P Balcerzak, et al.
Cancer Research|May 1, 1992
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trialT J Panella, D C Smith, S C Schold, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 1, 1996
Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trialsC L Loprinzi, E M Messing, J R O'Fallon, et al.
Investigational New Drugs|June 1, 1988
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinomaP J Elson, L K Kvols, S E Vogl, et al.
Journal of the National Cancer Institute|December 2, 1992
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastineD L Trump, D C Smith, P G Ellis, et al.
Cancer Treatment Reports|March 1, 1987
Phase II studies of PCNU and bisantrene in advanced renal cell carcinomaP J Elson, R H Earhart, L K Kvols, et al.
Cancer Research|May 1, 1990
Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusionS C Remick, J L Grem, P H Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumorsE K Rowinsky, D A Noe, D L Trump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastasesJ A Neidhart, S A Anderson, J E Harris, et al.
Cancer Treatment Reports|February 1, 1987
High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group StudyD L Trump, P J Elson, E C Borden, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomasK Antman, J Crowley, S P Balcerzak, et al.
Cancer Research|May 1, 1992
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trialT J Panella, D C Smith, S C Schold, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 1, 1996
Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trialsC L Loprinzi, E M Messing, J R O'Fallon, et al.
Investigational New Drugs|June 1, 1988
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinomaP J Elson, L K Kvols, S E Vogl, et al.
Journal of the National Cancer Institute|December 2, 1992
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastineD L Trump, D C Smith, P G Ellis, et al.
Cancer Treatment Reports|March 1, 1987
Phase II studies of PCNU and bisantrene in advanced renal cell carcinomaP J Elson, R H Earhart, L K Kvols, et al.
Cancer Research|May 1, 1990
Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusionS C Remick, J L Grem, P H Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumorsE K Rowinsky, D A Noe, D L Trump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastasesJ A Neidhart, S A Anderson, J E Harris, et al.
Cancer Treatment Reports|February 1, 1987
High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group StudyD L Trump, P J Elson, E C Borden, et al.
Pageof 15